MLTX icon

MoonLake Immunotherapeutics

118 hedge funds and large institutions have $3.21B invested in MoonLake Immunotherapeutics in 2023 Q3 according to their latest regulatory filings, with 47 funds opening new positions, 31 increasing their positions, 26 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

more first-time investments, than exits

New positions opened: | Existing positions closed:

more funds holding

Funds holding:

more repeat investments, than reductions

Existing positions increased: | Existing positions reduced:

more capital invested

Capital invested by funds: $ → $

0% more funds holding in top 10

Funds holding in top 10: 1010 (0)

23.14% less ownership

Funds ownership: 128.44%105.3% (-23%)

91% less call options, than puts

Call options by funds: $5.47M | Put options by funds: $61.8M

Holders
118
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$5.47M
Puts
$61.8M
Net Calls
Net Calls Change

Top Sellers

1 -$38.6M
2 -$32.6M
3 -$20.9M
4
AG
Artal Group
Luxembourg
-$20.4M
5
PBA
Paradigm Biocapital Advisors
New York
-$18.9M
Name Holding Trade Value Shares
Change
Change in
Stake
76
$806K
77
$793K
78
$775K
79
$764K
80
$717K
81
$651K
82
$646K
83
$570K
84
$570K
85
$547K
86
$539K
87
$530K
88
$462K
89
$401K
90
$394K
91
$391K
92
$365K
93
$351K
94
$327K
95
$309K
96
$293K
97
$293K
98
$284K
99
$248K
100
$246K